Iron Supplementation in Polycythemia Vera With Low Ferritin
Iron supplementation is generally avoided in polycythemia vera (PV) because phlebotomy–induced iron deficiency is a functional part of hematocrit control. [1] Low ferritin in PV should be managed by optimizing PV therapy and phlebotomy strategy rather than routine iron replacement. [1]
Treatment Objective in Polycythemia Vera
The hematocrit target in PV is less than 45%. [1] Phlebotomy is used to maintain the hematocrit target. [1]
Mechanism of Iron Deficiency During Phlebotomy
Frequent phlebotomies lower iron stores and produce iron deficiency. [1] This iron-restricted state limits marrow erythropoiesis during ongoing phlebotomy-based management. [2]
Guideline-Based Stance on Routine Iron Replacement
Iron supplementation is generally avoided in the setting of PV. [1] This avoidance is intended to prevent iron repletion from increasing erythrocytosis and thereby increasing the intensity of phlebotomy required to maintain hematocrit control. [2]
Evidence on Clinical Consequences of Iron Deficiency
Iron deficiency in treated PV has not been shown to increase whole-blood viscosity at a fixed erythrocyte volume fraction. [3] Iron deficiency develops during venesection-based therapy and can be tracked using serum ferritin and other iron-status markers. [4]
Considerations When Symptomatic Iron Deficiency Is Present
Iron supplementation is not routinely recommended in PV with low ferritin because repletion can worsen erythrocytosis and increase phlebotomy needs. [2] When symptoms of iron deficiency are clinically significant, PV management should be reassessed to reduce phlebotomy intensity (for example, via cytoreductive therapy when indicated) rather than using routine iron replacement as the primary intervention. [1]
Management Algorithm for Low Ferritin in PV
- Confirm iron deficiency with iron studies including ferritin and consider other iron-status indicators. [4]
- Maintain PV hematocrit control with phlebotomy using the hematocrit target of less than 45%. [1]
- Avoid routine oral or parenteral iron repletion solely for low ferritin. [1]
- Reassess PV control strategy when iron deficiency becomes symptomatic, with emphasis on reducing phlebotomy burden. [1]
Targets for Monitoring and Ongoing Adjustment
The hematocrit target should remain less than 45%. [1] Iron status should be monitored during phlebotomy-based management to characterize iron deficiency and guide reassessment of the overall PV treatment plan. [4]
Common Pitfalls to Avoid
Routine iron supplementation in PV with low ferritin can worsen erythrocytosis and increase the frequency of phlebotomy required for hematocrit control. [2] Assuming that low ferritin in PV requires direct iron replacement without adjustment of PV therapy can lead to increased phlebotomy needs. [1]
When Iron Replacement May Be Considered in Practice
Iron replacement is generally not used as a standard response to low ferritin in PV because it can destabilize hematocrit control. [1] Iron repletion should be approached only through a coordinated reassessment of PV management strategy aimed at reducing phlebotomy intensity and controlling hematocrit. [1]